



NDA 021520 S-035 S-036

SUPPLEMENT APPROVAL

Eli Lilly and Company
Attention: Ashraff Rampersaud, M.S. PMP
Manager, Global Regulatory Affairs, US
Lilly Corporate Center
Indianapolis, IN 46285

Dear Mr. Rampersaud:

Please refer to your Supplemental New Drug Applications (sNDAs) dated and received March 30, 2012 (S-035), and April 4, 2012 (S-036), submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Symbyax (olanzapine and fluoxetine HCl) Capsules 3 mg/25 mg, 6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg, 12 mg/50 mg.

We acknowledge receipt of your amendments dated August 3, 2012, August 22, 2012, September 18, 2012, and December 19, 2012.

These "Prior Approval" supplemental new drug applications provides for class labeling revisions to the **Contraindications, Dosage And Administration, Warnings and Precautions, Drug Interactions, Use in Specific Populations, Patient Counseling Information, & Medication Guide** regarding serotonin toxicity associated with the co-administration of linezolid and methylene blue as well as revisions related to persistent pulmonary hypertension of the newborn as requested in Agency supplement request letters dated March 2, 2012 and March 5, 2012.

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text agreed upon in your submission of December 19, 2012.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert, Medication Guide), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Keith Kiedrow, PharmD, RAC, Senior Regulatory Project Manager, at (301) 796-1924.

Sincerely,

{See appended electronic signature page}

Mitchell V. Mathis, M.D.
CAPT, USPHS
Director (acting)
Division of Psychiatry Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling
Medication Guide

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MITCHELL V Mathis
01/03/2013